Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00313599
Other study ID # UCSF CC#05591
Secondary ID
Status Completed
Phase Phase 1
First received April 11, 2006
Last updated July 1, 2014
Start date February 2006
Est. completion date December 2013

Study information

Verified date July 2014
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug. Lapatinib may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving lapatinib together with paclitaxel may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when given together with paclitaxel in treating patients with advanced solid tumors.


Description:

OBJECTIVES:

Primary

- Determine the maximum tolerated dose (MTD) of a 2-day pulse of lapatinib that can be given prior to paclitaxel (albumin-stabilized nanoparticle formulation ) (ABI-007; Abraxane™) in patients with advanced solid tumor malignancies.

Secondary

- Define the toxicity of this regimen.

- Determine, preliminarily, the antitumor efficacy and safety of ABI-007 when preceded by a 2-day pulse of lapatinib.

- Characterize the potential of the molecular markers within circulating tumor cells as markers of response (e.g., HER2 and AKT) or apoptotic markers.

- Determine whether lapatinib given at MTD prior to ABI-007 alters the pharmacokinetic properties of the paclitaxel component of ABI-007.

OUTLINE: This is a does-escalation study of lapatinib. Patients are stratified according to dose level.

Patients receive oral lapatinib on days 1, 2, 8, 9, 15, and 16 and paclitaxel (albumin-stabilized nanoparticle formulation) (ABI-007; Abraxane™) IV over 30 minutes on days 3, 10, and 17. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 1-6 patients receive escalating doses of lapatinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicities.

PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed solid tumor, including the following tumor types:

- Breast cancer

- Non-small cell lung cancer

- Prostate cancer

- Bladder cancer

- Gastroesophageal junction cancer

- Ovarian cancer

- Germ cell tumor

- Advanced or metastatic disease

- No effective curative therapy exists

- Evaluable disease

- Measurable disease not required

- Bone-only disease allowed

- No progressing brain metastases

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy > 3 months

- Absolute neutrophil count = 1,500/mm^3

- Hemoglobin = 9.0 g/dL

- Platelet count = 100,000/mm^3

- Bilirubin normal

- AST/ALT = 2.5 times upper limit of normal

- Creatinine normal

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No serious intercurrent medical or psychiatric illness

- No serious active infection

- No gastrointestinal tract disease that would impair a patient's ability to take oral medication

- No history of significant cardiac disease, including any of the following:

- Congestive heart failure

- Symptomatic cardiac arrhythmias

- Unstable angina

- No pre-existing peripheral neuropathy = 2

PRIOR CONCURRENT THERAPY:

- Any number of prior therapies allowed

- Prior paclitaxel, tyrosine kinase inhibitor therapy, or endothelial growth factor inhibitors allowed

- At least 14 days since prior and no concurrent CYP3A4 inducers or herbal or dietary supplements

- At least 7 days since prior and no concurrent CYP3A4 inhibitors

- At least 6 months since prior and no concurrent amiodarone

- More than 1 month since prior chemotherapy, radiotherapy, hormonal therapy, or investigational anticancer agents

- Concurrent continued use of gonadal suppression agents (i.e., goserelin acetate or leuprolide acetate) allowed

- No antacids 1 hour before and after study drug administration

- No concurrent retinoids

- No concurrent hormonal anticancer agent

- No other concurrent anticancer chemotherapy or investigational anticancer agents

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
lapatinib

paclitaxel


Locations

Country Name City State
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of lapatinib in course 1 estimated to be 12 weeks Yes
Secondary Toxicity up to 12 weeks Yes
Secondary Anti-tumor efficacy and safety every 8 weeks until disease progression estimated to be 12 weeks Yes
Secondary Pharmacokinetics during the first 2 weeks of treatment 2 weeks Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A